{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:41:22Z","timestamp":1790066482228,"version":"4.0.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01326","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:30:48Z","timestamp":1560299448000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["Membranous Nephropathy (MN) Recurrence After Renal Transplantation"],"prefix":"10.3389","volume":"10","author":[{"given":"Patrizia","family":"Passerini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Malvica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Tripodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cerutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1681\/ASN.2004121080","article-title":"Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization","volume":"16","author":"Ronco","year":"2005","journal-title":"J Am Soc Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1053\/j.ajkd.2013.03.045","article-title":"Membranous nephropathy and nonsteroidal anti-inflammatory agents","volume":"62","author":"Nawaz","year":"2013","journal-title":"Am J Kidney Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/S0270-9295(03)00049-4","article-title":"Diagnosis and natural course of membranous nephropathy","volume":"23","author":"Glassock","year":"2003","journal-title":"Semin Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","article-title":"Pathophysiological advances in membranous nephropathy: time for a shift in patient's care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet."},{"key":"B6","first-page":"156","article-title":"Can prognostic factors assist therapeutic decisions in idiopathic membranous nephropathy?","volume":"23","author":"Ponticelli","year":"2010","journal-title":"J Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2215\/CJN.04160413","article-title":"Glomerular diseases: membranous nephropathy\u2013a modern view","volume":"9","author":"Ponticelli","year":"2014","journal-title":"Clin J Am Soc Nephrol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A (2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/ndt\/gfr247","article-title":"An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis","volume":"26","author":"Hoxha","year":"2011","journal-title":"Nephrol Dial Transplant."},{"key":"B11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1681\/ASN.2010090967","article-title":"Anti-phospholipase A2 receptor antibody in membranous nephropathy","volume":"22","author":"Qin","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e62151","DOI":"10.1371\/journal.pone.0062151","article-title":"Autoantibodies against phospholipase A2 receptor in korean patients with membranous nephropathy","volume":"8","author":"Oh","year":"2013","journal-title":"PLoS ONE."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ki.2012.486","article-title":"Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy","volume":"83","author":"Kanigicherla","year":"2013","journal-title":"Kidney Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1003066","article-title":"PLA2R autoantibodies and recurrent membranous nephropathy after transplantation","volume":"63","author":"Stahl","year":"2010","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1093\/ndt\/gfu252","article-title":"Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients","volume":"29","author":"Seitz-Polski","year":"2014","journal-title":"Nephrol Dial Transplant."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.jprot.2011.05.021","article-title":"Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: alfa-enolase and borderline antigens","volume":"74","author":"Bruschi","year":"2011","journal-title":"J Proteom."},{"key":"B20","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1681\/ASN.2008121259","article-title":"Autoimmunity in membranous nephropathy targets aldose reductase and SOD2","volume":"21","author":"Prunotto","year":"2010","journal-title":"J Am Soc Nephrol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2016010050","article-title":"An indirect immunofluorescence method facilitates detection of thrombospondin Type 1 domain-containing 7A-specific antibodies in membranous nephropathy","volume":"28","author":"Hoxha","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1009742","article-title":"Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy","volume":"364","author":"Stanescu","year":"2011","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1681\/ASN.2012070730","article-title":"Phospholipase A2 receptor (PLA2R1) sequence variants in idiopathic membranous nephropathy","volume":"24","author":"Coenen","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1681\/ASN.2012080771","article-title":"Interaction between PLA2R1 and HLA-DQA1 variants associates with anti-PLA2R antibodies and membranous nephropathy","volume":"24","author":"Lv","year":"2013","journal-title":"J Am Soc Nephrol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"13031","DOI":"10.1097\/MD.0000000000013031","article-title":"Association between the HLA-DQA1 rs2187668 polymorphism and risk of idiopathic membranous nephropathy: a PRISMA-compliant meta-analysis","volume":"97","author":"Bao","year":"2018","journal-title":"Medicine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.kint.2018.11.008","article-title":"Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2012","journal-title":"Kidney Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1093\/ndt\/gfq223","article-title":"Long-term outcome of renal transplantation in patients with idiopathic membranous glomerulonephritis (MN)","volume":"25","author":"Moroni","year":"2010","journal-title":"Nephrol Dial Transplant."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1111\/j.1600-6143.2009.02851.x","article-title":"Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies","volume":"9","author":"El-Zoghby","year":"2009","journal-title":"Am J Transplant."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1600-6143.2008.02237.x","article-title":"Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study","volume":"8","author":"Dabade","year":"2008","journal-title":"Am J Transplant."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1093\/ndt\/11.6.1129","article-title":"Membranous nephropathy: recurrence after kidney transplantation","volume":"11","author":"Marcen","year":"1996","journal-title":"Nephrol Dial Transplant."},{"key":"B31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0270-9295(03)00057-3","article-title":"Treatment of de novo and recurrent membranous nephropathy in renal transplant patients","volume":"23","author":"Poduval","year":"2003","journal-title":"Semin Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"790","DOI":"10.2215\/CJN.04120609","article-title":"Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation","volume":"5","author":"Sprangers","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.kint.2016.08.030","article-title":"Recent advances in our understanding of recurrent primary glomerulonephritis after kidney transplantation","volume":"91","author":"Cosio","year":"2017","journal-title":"Kidney Int."},{"key":"B34","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/00007890-198304000-00010","article-title":"De novo and recurrent membranous glomerulopathy following kidney transplantation","volume":"35","author":"Berger","year":"1983","journal-title":"Transplantation."},{"key":"B35","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00007890-198507000-00020","article-title":"Recurrent membranous glomerulonephritis in two renal transplants","volume":"40","author":"Obermiller","year":"1985","journal-title":"Transplantation."},{"key":"B36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1600-6143.2011.03818.x","article-title":"Increased risk of recurrence of membranous nephropathy after related donor kidney transplantation","volume":"12","author":"Andr\u00e9sd\u00f3ttir","year":"2012","journal-title":"Am J Transplant."},{"key":"B37","first-page":"144","article-title":"Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors","volume":"50","author":"Cosyns","year":"1998","journal-title":"Clin Nephrol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1097\/TP.0000000000000962","article-title":"Long-term kidney transplant outcomes in primary glomerulonephritis: analysis from the ERA-EDTA registry","volume":"100","author":"Pippias","year":"2016","journal-title":"Transplantation."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/ajt.13133","article-title":"Anti-phospholipase A2 receptor antibodies in recurrent membranous nephropathy","volume":"15","author":"Kattah","year":"2015","journal-title":"Am J Transplant."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1097\/TP.0000000000000630","article-title":"Antiphospholipase A2 receptor antibody levels predict the risk of posttransplantation recurrence of membranous nephropathy","volume":"99","author":"Quintana","year":"2015","journal-title":"Transplantation."},{"key":"B41","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/ctr.12711","article-title":"Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation","volume":"30","author":"Gupta","year":"2016","journal-title":"Clin Transplant."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","article-title":"Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications","volume":"100","author":"Grupper","year":"2016","journal-title":"Transplantation."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","author":"Larsen","year":"2013","journal-title":"Mod Pathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"419","DOI":"10.5414\/CNP70419","article-title":"Recurrence and spontaneous remission of membranous nephropathy after renal transplantation","volume":"70","author":"Liebl","year":"2008","journal-title":"Clin Nephrol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int."},{"key":"B47","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S0272-6386(12)80685-8","article-title":"The recurrence of recurrent membranous glomerulopathy in a renal transplant recipient: case report and literature review","volume":"24","author":"Josephson","year":"1994","journal-title":"Am J Kidney Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"738","DOI":"10.2215\/CJN.01080905","article-title":"Rituximab for idiopathic membranous nephropathy: who can benefit?","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin J Am Soc Nephrol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int."},{"key":"B50","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/sj.ki.5002215","article-title":"Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial","volume":"71","author":"Praga","year":"2007","journal-title":"Kidney Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1111\/j.1600-6143.2006.01502.x","article-title":"Recurrent glomerulonephritis after kidney transplantation","volume":"6","author":"Choy","year":"2006","journal-title":"Am J Transplant."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1016\/j.transproceed.2006.10.109","article-title":"Initial response to immunosuppressive and renoprotective treatment in posttransplant glomerulonephritis","volume":"38","author":"Carneiro-Roza","year":"2006","journal-title":"Transplant Proc."},{"key":"B53","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/ncpneph0133","article-title":"Drug insight: rituximab in renal disease and transplantation","volume":"2","author":"Salama","year":"2006","journal-title":"Nat Clin Pract Nephrol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1111\/j.1600-6143.2006.01544.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient","volume":"6","author":"Gallon","year":"2006","journal-title":"Am J Transplant."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1681\/ASN.2012060577","article-title":"Recurrent membranous nephropathy in an allograft caused by IgG3k targeting the PLA2 receptor","volume":"23","author":"Debiec","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1159\/000371587","article-title":"Single-dose rituximab for recurrent glomerulonephritis post-renal transplant","volume":"41","author":"Spinner","year":"2015","journal-title":"Am J Nephrol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy: a one-year prospective study","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J Am Soc Nephrol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1681\/ASN.2015101170","article-title":"Immune response against autoantigen PLA2R Is not gambling: implications for pathophysiology, prognosis, and therapy","volume":"27","author":"Debiec","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1056\/NEJM198901053200102","article-title":"A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy","volume":"320","author":"Ponticelli","year":"1989","journal-title":"N Eng J Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"350","DOI":"10.6002\/ect.2016.0350","article-title":"Bortezomib as a novel approach to early recurrent membranous glomerulonephritis after kidney transplant refractory to combined conventional rituximab therapy","volume":"3","author":"Barbari","year":"2017","journal-title":"Exp Clin Transpl."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01326\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:30:52Z","timestamp":1560299452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01326\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,12]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2019.01326"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01326","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,12]]},"article-number":"1326"}}